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Background: Implantable cardioverter-defibrillators (ICDs) are intended to prevent sudden 
cardiac death yet also impose a risk of morbidity.  This study describes the outcomes of ICDs 
in a pediatric and congenital heart disease (CHD) population from a single center.   
 
Methods: Retrospective cohort study of all patients with an ICD followed at the University of 
Michigan Congenital Heart Center from 2005 – 2013. The primary outcome was ICD system 
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Results:  There were 191 ICD systems in 131 patients, including 57 with CHD, 24 with 
hypertrophic cardiomyopathy (HCM) and 45 with structurally normal hearts. Median age 
was 16 years at initial implant. Total follow-up was 850 patient-years; median 4.9 
years/patient. There were 43 (33%) patients that required 60 ICD revisions; 70 
revisions/1000 patient-years of follow-up. Revisions included 25 lead extractions with 
replacement, 21 lead additions, 5 lead repositions, and 4 full system revisions.  Kaplan-
Meier (K-M) median time to appropriate shock was similar to the median time to system 
revision. K-M time to system revision was significantly affected by recalled lead 
performance.  
 
Conclusions:  The need for ICD system revision is high in this pediatric and CHD population 
and occurs at a rate similar to the rate of receiving appropriate therapy. These results 
highlight the need for judicious implant criteria and improved device longevity.    
 




ICD=implantable cardioverter defibrillator 





Implantable cardioverter defibrillators (ICD) are a widely used therapy to prevent sudden cardiac 
death. Despite the life-saving potential of ICDs, they may impose significant morbidity. Device 
complications occur in up to 32% of pediatric and congenital heart disease (CHD) patients. (1-3) A 
recent study of primary prevention ICDs in this population showed that the risk of complication was 
greater than the risk of receiving an appropriate shock. (3)   
The most highlighted complication in many studies is inappropriate shocks which occur in 19-46% of 
pediatric and CHD patients compared to only 12% in the adult population. (2, 4-8)  Inappropriate 
shock risk may be attenuated with programming whereas complications such as lead failure may 
require system revision - increasing morbidity and the risk of mortality. (1, 9)   Many pediatric 
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2005-2008. (1,10-11) Even for non-recalled leads, the failure rate in pediatric patients is higher (2.3% 
per year) than in adult patients (0.6% per year). (1, 10-11) In some cases, lead extraction is necessary 
which imposes additional risk of major complications, including perforation and death. (9)  In other 
cases, failed leads may be abandoned and an additional lead placed, increasing the risk of vessel 
occlusion, a particular concern in younger children requiring a lifelong device.   
The goal of this study is to describe the outcomes of ICDs in a single center population of pediatric 
and CHD patients focusing on complications, specifically the need for system revision.  
Methods: 
This is a retrospective cohort study of all patients with an ICD followed at the University of Michigan 
Congenital Heart Center from 2005-2013 (including ICDs implanted prior to 2005). Patients were 
excluded if they had less than 6 months of follow up.  The primary outcomes were ICD system 
revision for any reason, defined as any operative procedure for device management, excluding 
routine generator changes for battery depletion; and first appropriate shock.   Data was collected 
from the electronic medical record, hospital device database, and industry remote monitoring 
databases (Medtronic Carelink, St Jude Merlin and Boston Scientific Latitude). The study was 
approved by the institutional review board.  In order to adequately describe the study population, 
patients were categorized into 4 groups based on type of heart disease:  1) congenital heart disease, 
2) structurally normal heart, 3) hypertrophic cardiomyopathy (HCM) and 4) non-HCM 
cardiomyopathies.  Patients with structurally normal hearts were those with diagnosed primary 
arrhythmia syndromes or idiopathic malignant ventricular arrhythmias.  Recalled leads were defined 
as those with a current recall: Medtronic Sprint Fidelis and St Jude Riata. Appropriateness of ICD 
delivered therapy was confirmed by review of device electrograms by pediatric electrophysiology 
providers.  Secondary prevention was defined as ICD implanted for aborted sudden cardiac arrest or 
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for the primary outcomes.  Deaths were censored.  Subgroup comparison included analysis of 
variance for continuous variables and chi-square or Fisher exact test for categorical variables; 
continuous variables by the GLM procedure (SAS 9.3, Cary, NC).  Patient specific analyses were 
limited to the first ICD revision only and for system specific analyses, ICD system revision was 
considered to result in a distinct ICD system, regardless of the amount of hardware replacement.   
Results:  
There were 191 ICD systems implanted in 131 patients; 43 patients (33%) required 60 ICD revisions.  
Device manufactures included 116 patients with Medtronic, 11 with Boston Scientific and 4 with St 
Jude; only 5% had epicardial or transvenous / epicardial hybrid devices.  Total follow up time was 
850 patient-years; median 4.9 (IQR 2.1-8.2) years per patient.  Clinical data by subgroup are 
presented in Table 1.  Of the 45 patients with structurally normal hearts, 37 had primary arrhythmia 
syndrome and 8 had an unknown cause of cardiac arrest.  Subgroups were similar with the 
exceptions that patients with CHD were older at ICD implant, patients with HCM were more likely to 
have a primary prevention ICD and patients with structurally normal hearts were more likely to 
receive an inappropriate shock.  There was no difference in risk of ICD revision in those less than 18 
years compared to those 18 years and older at the time of initial implant.   Patients with a secondary 
prevention ICD were more likely to have appropriate shocks (p = 0.4) and inappropriate shocks (p = 
<0.001) compared to those with primary prevention ICD.  There was no difference when comparing 
primary versus secondary devices and risk of system revision (p=0.14).  There were 3 known deaths 
during follow-up, all documented as unrelated to device function based on post-mortem 
interrogation.  
For the entire cohort, Kaplan-Meier median time to ICD revision (first system only) was 9.3 years, 
whereas median time to appropriate therapy, including ICD shock or anti-tachycardia therapy was 
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years of follow up. Median time to ICD revision for those devices implanted prior to 2012 (n=165) 
was stratified by year of implant (log rank p value = 0.0026) (Figure 2).  Time to device revision was 
similar for those implanted pre-2005 and those implanted 2009-2011 (log-rank p=0.5).   Devices 
implanted from 2005-2008 had a significantly shorter time to revision compared to those implanted 
pre-2005 (log rank p=0.001).  Time to revision was not statistically different between devices 
implanted 2005 – 2008 vs those implanted 2009-2011 (log rank p = 0.2); however this may be due to 
the limited follow-up of the latter device group and the high number of censored observations in 
this group.  To assure that old components (IE:leads) were not implicated in new implant revision 
rates during the most recent era, an additional Kaplan-Meier analysis was completed on only the 
first implanted device.  This also showed no era effect (log-rank p = 0.8).   
Due to the potentially significant impact that recalled leads may have had on the outcome, a second 
survival analysis was performed removing those lead models that had been recalled (n=116).   
Kaplan-Meier median time to ICD revision (first system only) was 10.4 years and median time to 
appropriate therapy was >15.2 years (log rank p value = 0.7; Figure 3).  There was no longer a 
significant difference in time to system revision by era when recalled leads were removed (Figure 4, 
n=157).  
Table 2 shows the indication for system revision.  There were 29 recalled leads in the study 
population -  16 (27% of total revisions) were implicated in revisions for lead fracture or malfunction 
and 3 functioning yet recalled leads  were revised because of parent request.  Revisions included 25 
lead extractions with replacements, 21 lead additions, 5 lead repositions, 4 full system revisions, and 
5 others (recalled generator replacement, placement of azygous or other coil for inadequate DFT).    
Comparing indications for early (<3 years) versus late (>5 years) revisions revealed lead malfunction 
or fracture accounting for 14 (42%) of early revisions and 15 (62%) of late revisions.  Lead 
malposition or dislodgement was the indication for 6 (18%) of the early revisions and none of the 
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Discussion: 
This study presents a unique perspective on ICD complications in a population of pediatric and 
congenital heart disease patients – namely, the risk of requiring ICD system revision after initial 
implant.  In this population, the median time to system revision was similar to the median time to 
appropriate therapy indicating that these patients were as likely to require a revision for device 
complication as they were to need the device’s life-saving capabilities.  The rate of system revision in 
this study was 7% per year.  This rate is twice that reported in a recent adult study showing a 3.5% 
per year rate of ICD revisions. (12) 
Most studies on ICD complications in pediatric and congenital heart disease patients assess all 
complications and typically highlight inappropriate shocks or other complications such as infection. 
(2-7) A recent study shows that 26% of pediatric patients with primary prevention ICDs required re-
intervention but did not elaborate on indication or timing. (3)  System revision is a major 
complication of ICD implantation, as it requires a surgical procedure which imposes morbidity and 
increases the risk of mortality.  In addition, system revision in young patients and patients with 
abnormally structured hearts can be more difficult due to distorted anatomy, small size and difficult 
venous access making the risk of mortality even higher. (1, 3)  Revisions are costly, requiring 
anesthesia, surgical costs, and hospital admission.  Notably, death is not an equivalent outcome to 
the temporary morbidity of most device complications.  However, the anticipated need for 
additional unplanned procedures is an important risk to discuss with patients and their families prior 
to ICD implantation, especially in those cases where the indications for implantation is primary 
prevention and definitive risk of sudden cardiac death may be unclear.   
To evaluate for any era effect in risk of system revision, time to revision was evaluated based on the 
year the device was implanted.  The system revision rate was significantly higher for those devices 
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time frame. (1)  Repeat analysis without including recalled leads reveals no era influence on time to 
revision.  This suggests that despite having improvement in technology of ICDs, and increased 
experience in ICD implantation, the risk of complications requiring system revision in this population 
is similar to 10 years ago.  Ideally, one might expect improved outcomes over time as technology and 
experience improve; however, this is not the observation in this study.   
Solutions for decreasing complications may include design improvement to enhance performance 
and longevity in leads commonly used in pediatric and congenital heart disease patients.  Specific 
design improvements targeted to this small portion of the device market may, in fact, have 
significant benefit to these patients.  Use of the subcutaneous ICD in children and patients with 
congenital heart disease may reduce the need for system revisions, and when necessary, should be 
lower risk procedures. (13)  Lastly, improved understanding of implant necessity, especially in those 
who do not meet a Class I indication may help to refine the target population.    This, in return, may 
decrease the use of ICD therapy and avoid these types of complications.   
This study was limited by its retrospective method.  Data was only as complete as the 
documentation in the medical record.  Complete follow-up would not have been captured for all 
patients who had changed medical systems.     Center specific practices and procedural techniques 
may contribute significantly to outcomes and risk of needing revision making.  During the study 
period, over 5 attending electrophysiologists and several advanced fellows participated in 
implantation of these patients. These data may not be optimally translated to other centers with 
different physicians and practices.  
Conclusions: 
The need for ICD system revision represents an important complication in the pediatric and CHD 
population; in this study, occurring at a rate similar to the rate of receiving appropriate therapy.  
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compared to earlier implanted devices. These data support further efforts to minimize complications 
related to ICDs.  These risks should be clearly discussed with families prior to the decision to implant 
an ICD.  
References 
1.  Atallah J, Erickson CC, Cecchin F, Dubin AM, Law IH, Cohen MI, LaPage MJ, et al. Multi-
institutional study of implantable defibrillator lead performance in children and young adults. 
Circulation 2013; 127:2392-2402.  
2. Kamp AN, Von Bergen NH, Henrikson CA, Makhoul M, Saarel EV, LaPage MJ, Russell MW, et al. 
Implanted defibrillators in young hypertrophic cardiomyopathy patients: a multicenter study. Pediatr 
Cardiol 2013; 34:1620-1627. 
3. DeWitt ES, Triedman JK, Cecchin F, Mah DY, Abrams DJ, Walsh EP, Gauvreau K, et al. Time 
dependence of risks and benefits in pediatric primary prevention ICD therapy. Circ Arrhythm 
Electrophysiol 2014; 7:1057-1063 
4.  Miyake CY, Webster G, Czosek RJ, Kantoch MJ, Dubin AM, Avasarala K & Atallah J. Efficacy of 
implantable cardioverter defibrillator in young patients with catecholaminergic polymorphic 
ventricular tachycardia: success depends on substrate. Circ Arrhythm Electrophysiol 2013; 6:579-587 
5. Lawrence D, Von Bergen N, Law IH, Bradley DJ, Dick M II, Frias PA, Streiper MJ, et al. Inappropriate 
ICD discharges in single-chamber versus dual-chamber devices in the pediatric and young adult 
population. J Cardiovasc Electrophysiol 2009; 20:287-290  
6.  Von Bergen NH, Atkins DL, Dick M II, Bradley DJ, Etheridge SP, Saarel EV, Fischbach PS, et al.  
Multicenter study of effectiveness of implantable cardioverter defibrillators in children and young 





This article is protected by copyright. All rights reserved. 
 
7.  Horner JM, Kinoshita M, Webster TL, Haglund CM, Friedman PA & Ackerman MJ. Implantable 
cardioverter defibrillator therapy for congenital Long QT syndrome: a single-center experience. 
Heart Rhythm 2010; 7:1616-1622. 
8.  Alter P, Waldhans S, Plachta E, Moosdorf R & Grimm W. Complications of implantable 
cardioverter defibrillator therapy in 440 consecutive patients. PACE 2005; 28:926-932 
9.  Matin M, Wilkoff BL, Brunner M, Cronin E, Love CJ, Bongiorni MG, Segreti L, et al.  Multicenter 
experience with extraction of the Riata/Riata ST ICD lead.  Heart Rhythm 2014; 11:1613-1618 
10. Hauser RG & Haynes DL. Increasing hazard of Sprint Fidelis implantable cardioverter-defibrillator 
lead failure. Heart Rhythm 2009; 6:605-610 
11. Kremers MS, Hammill SC, Berul CI, Koutras C, Curtis JS, Wang Y, Beachy J, et al. The national ICD 
registry report: version 2.1 including leads and pediatrics for years 2010 and 2011. Heart Rhythm 
2013; 10:e59-e65 
12.  Palmisano P, Accogli M, Zaccaria M, Luzzi G, Nacci F, Anaclerio M & Favale S. Rate, causes, and 
impact on patient outcome of implantable device complications requiring surgical revision: large 
population survey from two centres in Italy. Europace 2013;15:531-540. 
13. Petit SJ, Mclean A, Colquhoun I, Connelly D & McLeod K. Clinical experience of subcutaneous and 




Figure 1: Combined graphic of Kaplan-Meier time to event analysis for first ICD system revision 
(group 1) and first appropriate therapy (group 2)  
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Figure 2:  
Kaplan-Meier time to ICD revision for all ICD systems implanted prior to 2012 (n=165/191 systems 
included)  
Group 1 = devices implanted before 2005 
Group 2 = devices implanted 2005 – 2008 





This article is protected by copyright. All rights reserved. 
 
 
Figure 3: Combined graphic of Kaplan-Meier time to event analysis for first ICD system revision, 
excluding recalled leads (group 1) and first appropriate therapy (group 2)  
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Figure 4:  
Kaplan-Meier time to ICD revision for ICD systems implanted prior to 2012, excluding recalled leads 
(n=142-191 systems included) 
Group 1 = devices implanted before 2005 
Group 2 = devices implanted 2005 – 2008 










































Primary prevention 76 (58%) 35 (57%) 13 (28%) 
23 
(96%) 
5 (100%) <0.001 
Secondary 
prevention 
55 (42%) 22 (35%) 32 (71%) 1 (4%) 0 <0.001 















30 (23%) 17 (27%) 12 (27%) 3 (13%) 2(40%) 0.40 


















This article is protected by copyright. All rights reserved. 
 
 
Data presented as median (IQR) or count (%).  †Data included only those who had appropriate 
therapy. HCM = hypertrophic cardiomyopathy. CHD = congenital heart disease. CM = 
cardiomyopathy.  
Table 2 
Indication for Revision n= 60 (%) 
Lead malfunction/lead fracture 32 (53) 
Defibrillation failure† 7 (12) 
Lead malposition/dislodgement 5 (8) 
Elective lead replacement due to recall (per parents) 3 (5) 
Add atrial lead for rhythm detection 3 (5) 
Infection 3 (5) 
Loose header 2 (3) 
Lead perforation 2 (3) 
Other 3 (5) 
† Delivery of an appropriate device discharge that fails to convert the patient to a normal rhythm 
Inappropriate 
shock 
39 (30%) 15 (35%) 20 (45%) 4 (17%) 0 0.03 
Patients w/ revision 42 (32%) 21 (34%) 16 (35%) 5 (21%) 0 0.23 
 
